The mouse uterotrophic assay: a reevaluation of its validity in assessing the estrogenicity of bisphenol A. by Markey, C M et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 1 | January 2001 55
The Mouse Uterotrophic Assay: A Reevaluation of its Validity in Assessing
the Estrogenicity of Bisphenol A
Caroline M. Markey, Cheryl L. Michaelson, Electra C. Veson, Carlos Sonnenschein, and Ana M. Soto
Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, Massachusetts, USA
Estrogens exert a powerful inﬂuence on the
development, regulation, and endocrine con-
trol of the female genital tract and mammary
glands. Their capacity to induce cell prolifer-
ation in estrogen-target tissues underlies the
critical role that these steroid hormones also
play in carcinogenesis. Therefore, the dis-
turbing revelation that synthetic chemicals
have the capacity to mimic the effects of
estrogens presents a very real concern for
human health, particularly when exposure
occurs at stages of tissue organization and
development such as in prenatal or neonatal
individuals. The fact that these chemicals do
not necessarily share a similar structure to
estrogen is further confounding. One such
chemical is bisphenol A (BPA). This
monomer is used in the manufacture of poly-
carbonates and epoxy resins from which a
plethora of products are generated, including
food and beverage containers, dental sealants,
and babies’ bottles. The propensity of BPA to
leach from such products under normal con-
ditions (1–5) highlights the need to investi-
gate its potential for inducing developmental
and reproductive abnormalities in humans. 
Numerous studies conducted in vitro
attest to the estrogenic character of BPA.
This chemical has been shown to induce cell
proliferation in MCF-7 cells (2,6,7), stimu-
late the release of prolactin from pituitary
GH3 cells (8), and induce transcriptional
activation of the estrogen receptor (ER) in
both yeast-based assays (9) and human
embryonal kidney cells via the estrogen
response element (10). BPA has also been
shown to up-regulate the expression of vitel-
logenin mRNA in primary hepatocytes
derived from male Xenopus laevis (11).
However, few studies have addressed the
effects of in utero exposure to environmen-
tally relevant doses of BPA in vivo. One
study in male CF-1 mice described a signiﬁ-
cant increase in adult prostate weight after in
utero exposure to BPA concentrations as low
as 2 and 20 µg (12). Although this research
establishes effective doses of BPA in males
using prostate weight as an end point, it is
limited when extrapolating to studies in the
female reproductive tract. Because this is the
focus of our work, it is imperative to estab-
lish a dose–response range in female mice
using an appropriate end point in a classical
estrogen-target organ such as the uterus. 
One established method for determining
the estrogenicity of a chemical is the rodent
uterotrophic assay, which measures an
increase in wet weight of the uterus (13). Yet,
a review of this method reveals a confounding
range of results that points to species-speciﬁc
and even strain-specific differences in the
magnitude of the uterotrophic response to
BPA. Fischer 344 rats (ovariectomized), the
strain that is most sensitive to BPA exposure,
exhibit an approximately 2-fold increase in
uterine wet weight after 3 days exposure to
0.3 mg/kg BPA delivered via a subcutaneous
implant (14). Sprague Dawley rats (ovariec-
tomized) exhibit less sensitivity because the
same dose elicits no effect (14); 10 mg/kg
BPA administered orally for 4 days induces a
1.4-fold increase in wet weight (15).
Immature Alpk:AP rats exhibit a uterotrophic
response to 400 mg/kg BPA as evidenced by
1.3-fold and 1.5-fold increases in wet weight
after oral gavage and subcutaneous injection,
respectively (16). The few studies conducted
in mice reflect a greater uterotrophic resis-
tance to BPA. Immature CFLP mice do not
respond to 3 days subcutaneous injection of
0.5 mg BPA/mouse (approximately 16.7
mg/kg), yet 5 mg (approximately 167 mg/kg)
causes toxicity to the animals (17). CD-1
mice show particular resistance to the effects
of estradiol on the basis of testicular measure-
ments (18), and they may be equally unre-
sponsive to estrogen mimics such as BPA.
These data clearly demonstrate the
absence of a systematic dose–response curve
to BPA in any species or strain of rodent. In
this paper we address the topic of suscepti-
bility to BPA using the immature CD-1
mouse as a model. Because CD-1 mice are
outbred for large litter size, they are useful
for studies on the developmental and repro-
ductive consequences of environmental hor-
mones. Therefore, there is a need to establish
the suitability of this strain for toxicology
studies in female development and reproduc-
tion. In addition, we investigated the validity
of the classical mouse uterotrophic assay
because much of the confounding data
regarding the effect of BPA in vivo is based
on this method. We accomplished this by
comparing the changes in uterine wet weight
with three other end points that reﬂect estro-
genic activity within the uterus, namely
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The prevalence of synthetic chemicals in our environment that are capable of mimicking the
female hormone estrogen is a growing concern. One such chemical, bisphenol A (BPA), has been
shown to leach from a variety of resin-based and plastic products, including dental sealants and
food and beverage containers, in concentrations that are sufﬁcient to induce cell proliferation in
vitro. The response to BPA in vivo has been varied; thus the aims of this study were to investigate
a) whether BPA has an estrogenic effect in CD-1 mice, a strain that is useful for developmental
studies; and b) whether the uterotrophic assay is a valid means of determining the estrogenicity of
BPA by comparing it with other end points measured in the uterus. Immature female CD-1 mice
were exposed to BPA in concentrations ranging from 0.1 to 100 mg/kg body weight for 3 days.
Results showed that BPA induced a significant increase in the height of luminal epithelial cells
within the uterus at concentrations of 5, 75, and 100 mg/kg and that BPA induced lactoferrin at
concentrations of 75 and 100 mg/kg. A uterotrophic response (increase in uterine wet weight)
was induced by 100 mg/kg BPA only. Further, the proportion of mice showing vaginal opening
was greater after exposure to 0.1 and 100 mg/kg BPA, relative to the control animals and those
receiving intermediate doses of BPA. These results demonstrate that BPA induces changes in the
mouse uterus that differ depending on the exposure dose and the end point measured, and reveal
that certain tissue effects show a nonmonotonic relationship with dose. These data also demon-
strate that BPA induces estrogenic changes in the uterus of the CD-1 mouse, and highlight the
need to reevaluate the validity of the mouse uterotrophic assay as an end point for determining
the estrogenicity of suspected environmental estrogens. Key words: bisphenol A, CD-1 mouse,
endocrine disruptors, lactoferrin, morphometrics, nonmonotonic dose–response curves,
uterotrophic assay. Environ Health Perspect 109:55–60 (2001). [Online 12 December 2000]
http://ehpnet1.niehs.nih.gov/docs/2001/109p55-60markey/abstract.htmlepithelial cell morphology, induction of the
estrogen-inducible protein lactoferrin, and
expression of proliferating cell nuclear antigen
(PCNA). 
Materials and Methods
Animals. Immature female CD-1 mice
(Charles River Laboratories, Wilmington,
MA) were maintained in a temperature-con-
trolled room on a 14 hr light:10 hr dark cycle
in the Tufts University-New England Medical
Center animal facility. Mice were fed RMH
3000 rodent diet (Agway Inc., Syracuse, NY)
that tested negligible for estrogenicity, and
water was supplied from glass bottles only.
Cages and bedding also tested negative for
estrogenicity using the E-SCREEN assay
(19). All experimental procedures were
approved by the Tufts University-New
England Medical Center Animal Research
Committee.
Vaginal opening. Before 23-day-old
female mice were exposed to dimethyl sul-
foxide (DMSO), BPA, or estradiol (E2),
they were checked to see if their vaginas had
opened. This typically occurs in mice
around 35 days of age under the influence
of estrogens and represents the initial stages
of attaining sexual maturity. Before sacriﬁce
at 26 days of age, mice were checked for
vaginal opening again. We established two
populations: one in which the vagina
showed the beginning of a perforation but
was not completely canalized (termed partial
opening), and another showing complete
canalization and patency (termed complete
opening). 
Uterotrophic assay. At 23 days of age,
mice were weighed and divided randomly
into 10 experimental groups (n = 4–22). We
performed morphometric analyses on a sub-
set of these animals (n = 4–12) that were
randomly chosen. Nine of the groups were
implanted with Alzet osmotic pumps (Alza
Corp., Palo Alto, CA) containing either
DMSO (vehicle), BPA, or E2 (Sigma, St.
Louis, MO); another group acted as an
untreated control (no pumps were
implanted). BPA and E2 were dissolved in
DMSO, and the pumps were prepared in
accordance with the manufacturer’s instruc-
tions to deliver BPA to mice in concentra-
tions of 0.1, 0.5, 1, 5, 50, 75, and 100
mg/kg body weight/day, and E2 at a concen-
tration of 5.0 µg/kg body weight/day. This
dose of E2 has been shown to induce a 2-
fold increase in uterine wet weight (20).
Pumps were implanted subcutaneously in
mice under aseptic conditions. After 3 days
mice were weighed and sacriﬁced by cervical
dislocation, and their uteri were dissected
out. Each uterus was blotted and the wet
weight recorded. Data were expressed as a
percentage of the body weight. 
Histology
The uteri were immediately fixed in 4%
formaldehyde in 0.1 M phosphate buffered
saline (PBS; pH 7.4) for 10 hr. One horn of
each uterus was dissected transversely into
three segments. Tissue was processed through
a series of alcohols and xylene, inﬁltrated with
Paraplast paraffin (Fisher, Pittsburgh, PA)
under vacuum, and embedded in paraffin.
Five-micron sections were cut on a Sorvall JB-
4 microtome (DuPont, Wilmington, DE),
mounted on Superfrost positive charged slides
(Fisher) and stained to determine a) changes
in the luminal and glandular epithelium by
morphometric analysis; b) immunolocaliza-
tion of lactoferrin, an estrogen-inducible pro-
tein; and c) immunolocalization of PCNA to
assess cell proliferation.
Morphometric analyses. Sections of uterus
were stained with hematoxylin and eosin and
prepared for light microscopy. The relative
area of the uterine endometrium occupied
by the mucosa (luminal epithelium, glandu-
lar epithelium, and lamina propria) and
myometrium, and the height of the luminal
epithelium were determined using the pro-
gram Bioscan Optimus (Version 1.13; Media
Cybernetics, Silver Springs, MD). We mea-
sured relative areas of uterine tissue compart-
ments using the 10×  objective and epithelial
cell height using the 20×  objective. For
epithelial cell height, we measured only areas
of epithelium in which the nucleus and base-
ment membrane of single cuboidal/columnar
epithelial cells could be seen. Four areas in
each of three transverse sections of uterus
were analyzed per animal. For the parameter
of epithelial cell height, four measurements
were made within four areas of the three
transverse sections of each uterus per animal.
Immunohistochemistry
Lactoferrin. Lactoferrin was localized within
the uterine epithelium by immunofluores-
cence (21). Sections were hydrated and
microwaved in 10 mM citrate buffer (pH 6)
for antigen retrieval (22); nonspeciﬁc bind-
ing was blocked with 5% normal goat
serum and 5% normal rabbit serum in
0.01 M PBS. Sections were incubated
overnight at 4°C in a humid chamber with
a rabbit antibody raised to mouse lactoferrin
(monoclonal IgG, 1:100; supplied by
Christina Teng, National Institute of
Environmental Health Sciences, Research
Triangle Park, NC). Biotinylated goat anti-
rabbit IgG (1:400; Roche Diagnostics
Corp., Indianapolis, IN) was applied to sec-
tions, and lactoferrin was visualized by strep-
tavidin Alexa Fluor conjugate (Molecular
Probes, Eugene, OR). Sections were coun-
terstained with Hoechst 33258 (1:1000;
Sigma) and mounted in glycerol/0.01 M
PBS (1:1). Fluorescent images were captured
using a SPOT-Real Time digital camera
(Diagnostic Instruments, Inc., Sterling
Heights, MI) attached to a Zeiss Axioskop
(Carl Zeiss, Inc., Thornwood, NY) and ana-
lyzed in the SPOT-Real Time program.
We semiquantitatively determined (using
the 20× objective) the expression of lactofer-
rin within the luminal and glandular epithe-
lium of the uterus by assessing the intensity of
staining within both the apical and basal
regions of the cells. The intensity of staining
ranged from 0 to 3, with 3 representing the
most intense staining, similar to that observed
in the estradiol group. The four scores (lumi-
nal apical, luminal basal, glandular apical, and
glandular basal) were summed; thus maximal
staining was represented by a score of 12.
Four areas in each of the three transverse sec-
tions of uterus were analyzed per animal.
PCNA. Immunohistochemical staining of
PCNA was performed using the avidin-
biotin-immunoperoxidase method. Sections
were hydrated and microwaved in 10 mM
citrate buffer (pH 6) for antigen retrieval;
both endogenous peroxidase and nonspeciﬁc
binding were then blocked with 0.3% H2O2
in methanol and 1.5% normal goat serum in
0.01 M PBS, respectively. Sections were incu-
bated overnight in a humid chamber at 4˚C
with anti-PCNA mouse antibody (mono-
clonal IgM; Beckman Coulter, Miami, FL) at
a dilution of 1:500. Mouse IgM preimmune
serum was used at the same concentration as
the primary antibody to provide an isotypic
control. We applied the biotinylated sec-
ondary antibody (IgM) and avidin-peroxidase
(Vectastain ABC Kit; Vector Laboratories,
Burlingame, CA) to sections according to the
manufacturer’s instructions and visualized
peroxidase activity by diaminobenzidine
(Sigma). Sections were lightly counterstained
with hematoxylin and prepared for light
microscopy.
The expression of PCNA within the
luminal epithelium of the uterus was deter-
mined by densitometric image analysis using
Scion Image (Scion Corporation, Frederick,
MD). Video images of the sections were cap-
tured using the 40× objective and calibrated
so that the cytoplasm read 0 (0%) average
gray value (AGV) and the darkest nucleus
read 255 (100%) AGV. Those nuclei with
an AGV near 217 (representing 15% of the
highest intensity range) were counted as pos-
itive for PCNA. Data are presented as the
number of PCNA-positive stained nuclei per
1,000 µm basement membrane. We assessed
a total length of 5000–10,000 µm basement
membrane from three cross-sectional areas of
the uterus per animal.
Statistical Analysis
There was no signiﬁcant difference between
the control group and vehicle group for all
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then performed against these combined data.
We analyzed uterine wet weight (as a per-
centage of body weight) and the relative area
of luminal and glandular epithelium by one-
way analysis of variance using a Tukey’s post
hoc comparison. Body weight, uterine wet
weight (absolute), the relative area of lamina
propria and myometrium, epithelial cell
height, and PCNA labeling were analyzed by
a Kruskal-Wallis test because data were not
normally distributed. Lactoferrin induction
was analyzed by a Kruskal-Wallis test, as this
data was nonparametric in nature. We deter-
mined differences between the control group
relative to each treatment group using
Bonferroni-adjusted Mann-Whitney tests,
and evaluated the percentage of mice show-
ing vaginal opening on day 26 (sacrifice)
using a two-sample Z test. The analysis com-
pared the control group to each treatment
group. Results were considered signiﬁcant at
p < 0.05. We performed a Pearson’s correla-
tion test on the body weight and uterine wet
weight data for each treatment group; results
were considered signiﬁcant at p < 0.01.
Results
There was an overall significant difference
between the control group and the experi-
mental treatments (BPA groups and E2) for
body weight (p < 0.05), uterine wet weight (p
< 0.0001), uterine wet weight per body
weight (p < 0.0001), relative area of luminal
epithelium (p < 0.0001), relative area of lam-
ina propria (p < 0.0001), height of the lumi-
nal epithelial cells (p < 0.0001), and
lactoferrin expression (p < 0.0001). The
Pearson’s correlation test revealed a signiﬁcant
correlation between body weight and uterine
wet weight after exposure to 75 mg/kg BPA
and estradiol only (p < 0.01). There was no
significant difference between the control
group and experimental treatment groups for
the relative area of glandular epithelium and
myometrium and PCNA labeling. All data
are presented in Tables 1, 2, and 3.
Vaginal Opening
The proportion of mice showing vaginal
opening (completely open and partially open
combined) on day 26 after 3 days exposure to
DMSO, BPA, or E2 was signiﬁcantly differ-
ent between groups (Table 1). Relative to the
control group, a greater proportion of mice
exposed to 0.1 mg/kg BPA (p < 0.0001), 100
mg/kg BPA (p < 0.0001), and E2 (p <
0.0001) showed vaginal opening. Although
not statistically signiﬁcant (p = 0.0512), mice
exposed to 75 mg/kg BPA also showed an
increased incidence of vaginal opening (com-
pletely open and partially opened combined)
relative to the control group.
Body Weight
BPA induced a significant increase in body
weight at a concentration of 0.5 mg/kg (p <
0.05) and a significant decrease in body
weight at 100 mg/kg (p < 0.05; Table 1).
These represented changes in body weight of
12% and 10%, respectively. 
Uterotrophic Assay
The administration of BPA at concentrations
of 0.1–75 mg/kg body weight had no effect
on the wet weight of the uterus relative to the
control group. There was a 53% increase in
uterine wet weight in response to 100 mg/kg
body weight BPA (p < 0.05) and a 308%
increase in uterine wet weight in response to
E2 (positive control group; p < 0.0001) rela-
tive to the control group. Wet weight of the
uterus, calculated as a percentage of the body
weight, showed a similar pattern of change
(Table 1, Figure 1). 
Uterine Morphology
Luminal epithelium. The relative area of
luminal epithelium within the uterus was
not affected by BPA at any concentration. E2
treatment induced a significant increase in
this parameter by 115% relative to the con-
trol group (p < 0.0001) (Table 2, Figure 1). 
The uterus exhibited an increase in
epithelial cell height in response to BPA at
concentrations of 5 (p < 0.05), 75, and 100
mg/kg (p < 0.0001), which represents
increases of 14, 42, and 63%, respectively.
Although not statistically significant (p =
0.056), epithelial cell height also increased in
response to 50 mg/kg BPA. Treatment with
E2 induced an 83% increase (p < 0.0001) in
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Table 1. Body weight, uterine wet weight (expressed as absolute values and as a percentage of body weight), and the percentage of mice showing vaginal open-
ing at sacriﬁce in immature CD-1 mice implanted for 3 days with subcutaneous pumps containing DMSO vehicle, BPA, or E2. 
Body weight Uterine wet weight Uterine wet weight Vaginal opening at day 26 (%)
Treatment  (mg) (mg) (per body weight) Complete Complete and partial
Control 15. 89 ± 0.38 19.01 ± 1.16 0.1195 ± 0.0064ab 27 (13/48) 40 (19/48)
E2 (5 µg/kg) 16.90 ± 1.06 77.62 ± 4.97* 0.4612 ± 0.0159c 91 (20/22)* 95 (21/22)*
0.1 mg/kg BPA 17.50 ± 0.72 24.30 ± 4.11 0.1374 ± 0.0020abd 100 (5/5)* 100 (5/5)*
0.5 mg/kg BPA 17.80 ± 0.32* 20.35 ± 1.40 0.1143 ± 0.0078ab 55 (6/11) 64 (7/11)
1 mg/kg BPA 16.22 ± 0.35 16.08 ± 1.84 0.0984 ± 0.0096ab 45 (5/11) 45 (5/11)
5 mg/kg BPA 16.32 ± 0.63 15.54 ± 1.89 0.0938 ± 0.0086a 41 (7/17) 47 (8/17)
50 mg/kg BPA 15.82 ± 0.64 19.13 ± 1.40 0.1236 ± 0.0105ab 24 (4/17) 59 (10/17)
75 mg/kg BPA 14.92 ± 0.50 23.74 ± 1.94 0.1580 ± 0.0078bd 67 (4/6) 67 (4/6)
100 mg/kg BPA 14.39 ± 0.44* 29.08 ± 2.87* 0.2013 ± 0.0169d 100 (6/6)* 100 (6/6)*
Values for each group are expressed as mean ± SEM. The control group represents pooled data from the control and vehicle groups. For uterine wet weight (per body weight), mean values
with no superscripts in common are signiﬁcantly different (p < 0.05). 
*Signiﬁcantly different from the control group (p < 0.05). 
Table 2. Morphometric analyses of uterine tissue from immature CD-1 mice implanted for 3 days with subcutaneous pumps containing DMSO vehicle, BPA, or E2.
Relative area (%)
Treatment Luminal epithelium Glandular epithelium Lamina propria Myometrium Height of epithelium
Control 12.11 ± 0.78a 1.69 ± 0.17a 48.52 ± 1.38 36.93 ± 1.83 14.39 ± 0.54
E2 (5 µg/kg) 25.98 ± 1.09b 1.34 ± 0.19a 40.16 ± 1.28* 33.78 ± 1.26 26.31 ± 1.12*
0.1 mg/kg BPA 11.76 ± 1.12a 2.07 ± 0.55a 51.83 ± 3.07 35.50 ± 3.74 14.56 ± 1.11
0.5 mg/kg BPA 15.07 ± 1.84a 1.33 ± 0.30a 50.50 ± 1.10 33.75 ± 1.78 16.46 ± 0.92
1 mg/kg BPA 11.77 ± 1.92a 1.77 ± 0.37a 49.69 ± 0.81 36.78 ± 2.23 15.83 ± 0.76
5 mg/kg BPA 12.36 ± 0.88a 2.10 ± 0.33a 42.27 ± 1.46* 43.05 ± 2.37 16.46 ± 0.60*
50 mg/kg BPA 12.93 ± 0.71a 1.30 ± 0.21a 48.01 ± 1.56 37.75 ± 1.65 16.13 ± 0.47
75 mg/kg BPA 12.61 ± 0.97a 1.95 ± 0.39a 53.00 ± 0.56 32.44 ± 0.80 20.43 ± 0.97*
100 mg/kg BPA 15.45 ± 1.27a 1.80 ± 0.40a 49.17 ± 4.24 34.56 ± 4.81 23.46 ± 0.74*
Values for each group are expressed as mean ± SEM. For luminal epithelium and glandular epithelium, mean values within each column with no superscripts in common are signiﬁcantly
different (p < 0.05).
*Signiﬁcantly different from the control group (p < 0.05).epithelial cell height relative to the control
group (Table 2, Figures 1 and 2).
Glandular epithelium. The relative area
of glandular epithelium within the uterus
was not affected by treatment with BPA or
E2 at any concentration compared to the
control group (Table 2).
Lamina propria and myometrium.
Compared to the control group, the relative
area of lamina propria within the uterus was
not affected by any concentration of BPA
except 5 mg/kg (p < 0.01); E2 also induced a
significant decrease in the relative area of
lamina propria (p < 0.01). The relative area
of myometrium within the uterus was not
affected by treatment with BPA or E2 at any
concentration (Table 2).
Lactoferrin
Within the luminal and glandular epithe-
lium of the uterus, BPA induced a signifi-
cant increase in the expression of lactoferrin
by 373% at a concentration of 75 mg/kg (p
< 0.01) and by 438% at a concentration of
100 mg/kg (p < 0.01) relative to the control
group. In some animals, lactoferrin expres-
sion was induced at a concentration of 50
mg/kg BPA, although this was not statisti-
cally signiﬁcant (Figure 3). At all lower BPA
concentrations, lactoferrin expression was
not induced. The expression of lactoferrin
was increased by 405% in the E2 group (p <
0.01), whereas the control group showed no
response (Table 3, Figure 3). 
PCNA
There was no significant difference in the
expression of PCNA in the luminal epithe-
lium between treatment groups (Table 3).
Discussion
BPA has the capacity to induce proliferative
and stimulatory changes in estrogen target
tissues that are analogous to those induced
by estrogens. These effects have been identi-
ﬁed in various strains of rat after exposure to
concentrations from 0.3 to 800 mg BPA/kg
body weight. The ensuing morphologic
changes include proliferation of mammary
gland epithelium (23), cell proliferation and
cornification of the vagina (14,24), and an
increase in the wet weight, epithelial cell
height, and mucous secretion of the uterus
(14,16). In the present study we have
demonstrated that CD-1 mice are also
responsive to BPA and that concentrations
from 5 to 100 mg/kg body weight can
induce a statistically significant increase in
the height of luminal epithelial cells; we have
also demonstrated that 0.1 mg/kg BPA can
induce vaginal opening. Only 100 mg/kg
BPA can induce a uterotrophic response.
These changes were not accompanied by a
change in the relative area of uterus occupied
by luminal epithelium, glandular epithelium,
lamina propria (except at 5 mg/kg BPA),
and muscle, which demonstrates that the
relationship between different tissue com-
partments within the uterus remain the same
with BPA treatment. In contrast, the E2
group did show a signiﬁcant increase in both
epithelial cell height and relative area of
epithelium within the uterus. This demon-
strates that the single E2 dose used in the
study (known to induce a maximal response)
has a more profound effect than the BPA
doses that were assayed.
Although this study demonstrates that
BPA induces changes in the mouse reproduc-
tive tract at doses as low as 0.1 mg/kg, it high-
lights the phenomenon that each end point
measured reflects a different dose–response
proﬁle. The data for uterine wet weight sug-
gest a U-shaped profile because weight is
increased at 0.1 (although not statistically
significant) and 100 mg/kg BPA, yet drops
between 1 and 5 mg/kg BPA. Similarly, inci-
dence of vaginal opening is significantly
increased at 0.1 mg/kg BPA and again at
100 mg/kg BPA. Lactoferrin expression
shows a proﬁle in which the middle concen-
trations of BPA (e.g., 1 mg/kg) increase this
variable, whereas doses on either side have
absolutely no effect until they reach 75 and
100 mg/kg. These data suggest that exposure
to BPA induces a nonmonotonic response in
the reproductive parameters measured, a
ﬁnding that is consistent with other studies
in which E2 and the potent estrogen diethyl-
stilbestrol (DES) induce an inverted U-
shaped dose–response curve for prostate
weight (25). 
The glycoprotein lactoferrin has been
detected in signiﬁcant amounts in the lactat-
ing mammary gland (21,26), uterus, uterine
luminal fluid, cervix, vagina, ovary, and
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Table 3. Labeling of PCNA and lactoferrin within the uterus of the immature CD-1 mice implanted for 3
days with subcutaneous pumps containing DMSO vehicle, BPA, or E2. 
PCNA labeled Luminal and Lactoferrin 
Treatment luminal epitheliuma glandular epitheliumb expressionc
Control 20.75 ± 3.79 1.62 ± 0.25 0
E2 (5 µg/kg) 21.79 ± 5.34 8.18 ± 0.99* 100
0.1 mg/kg BPA NA NA NA
0.5 mg/kg BPA 22.29 ± 10.85 1.28 ± 0.26 0
1 mg/kg BPA 30.64 ± 7.93 1.79 ± 1.15 17
5 mg/kg BPA 30.64 ± 12.57 1.18 ± 0.47 0
50 mg/kg BPA 20.37 ± 8.16 2.36 ± 0.71 33
75 mg/kg BPA NA 7.67 ± 1.26* 100
100 mg/kg BPA NA 8.71 ± 0.60* 100
NA, not available. Values for each group are expressed as mean ± SEM. 
aNumber of labeled cells/1,000 µm basement membrane. bArbitrary units to a maximum of 12. cScore > 4 out of a possible
12 (%). *Signiﬁcantly different from the control group (p < 0.05).
Figure 1. Differences in relative area of luminal epithelium (the percentage of uterus occupied by luminal
epithelium), height of luminal epithelium, and uterine wet weight of immature mice exposed to BPA con-
centrations ranging from 0.1 to 100 mg/kg/day. C, untreated control. Bars represent mean values ± SEM. 
*Signiﬁcantly different (p < 0.05) relative to C and DMSO control groups combined. 
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Uterine wet weightoviduct of the mouse (21,27,28). A member
of the transferrin family, lactoferrin is
thought to provide bacteriocidal protection
for gametes (possibly both male and female)
in the uterus due to its chelating properties
(29,30) and may be implicated in fetal
growth and development (31). The expres-
sion of lactoferrin in the mouse is under
estrogenic control and shows ﬂuctuations in
concentration during the estrous cycle (32),
and in response to DES in a time- and dose-
dependent manner (21,33). As such, lacto-
ferrin is often used as a marker of estrogen
action. In the present study we demon-
strated that 75 and 100 mg/kg BPA induced
a > 300% increase in the immunolocaliza-
tion of lactoferrin in both the luminal and
glandular epithelium of the uterus. This
increase is of the same magnitude as that
induced by E2 in the current study and as
described in previous work (27), demon-
strating the estrogenic nature of BPA in vivo.
The difference in the sensitivity of individual
mice to BPA, which was particularly evident
in the measurement of lactoferrin expression
in the 50 mg/kg BPA group, may be a con-
sequence of intrauterine position during
development. The intrauterine position has
been shown to determine the level of
endogenous estrogens to which a developing
fetus is exposed on the basis of position rela-
tive to either a male or a female (34,35).
The null effect of BPA on the expression
of PCNA within the mouse uterus was most
likely due to high variation within treatment
groups. In retrospect, labeling of bromodeoxy
uridine (BrdU) may have provided a more
accurate account of cell proliferation because it
speciﬁcally indicates DNA synthesis, whereas
PCNA is also expressed in cells involved in
RNA transcription and cell repair (36). PCNA
has been shown to increase expression within
the mouse uterine epithelium during develop-
ment (37) and pregnancy (38). In one study
Karlsson et al. (39) describe a decrease in
PCNA expression in luminal epithelial cells of
the rat uterus in response to tamoxifen and
toremifene that is concomitant with an
increase in the expression of BrdU.
One of the aims of this study was to pro-
vide insight into effective doses of BPA in
vivo such that subsequent studies on the
effects of in utero exposure on development
and reproduction could be undertaken. The
current study revealed reproductive changes
within the immature CD-1 mouse (vaginal
opening) following 3 days exposure to BPA at
0.1 mg/kg body weight. Yet recent work in
CF-1 mice, a strain also outbred for large lit-
ter size, has revealed that in utero exposure to
2.4 µg BPA/kg body weight significantly
advances the onset of puberty in females (35).
Despite the lack of data on the effects of BPA
exposure on female reproductive tract mor-
phology in that study, the comparison with
our study demonstrates that caution must be
exercised in extrapolating the effective dose
for in utero exposure from studies carried out
in immature or adult animals. 
Earlier estimations of the estrogenic
potency of BPA suggested that this chemical
was a “weak” estrogen mimic, exhibiting a
relative binding affinity to both the ER-α
and β approximately 1:2,000 that of 17β -
estradiol (6,40). Because these are in vitro
studies, they do not take into account factors
such as uptake, transportation, and metabo-
lism of BPA speciﬁc to the live animal, which
modify the concentration of chemical avail-
able to bind the ER or other serum proteins
such as albumin, sex hormone-binding globu-
lin, and corticosteroid-binding globulin
(12,40–42). BPA binds both human sex
steroid-binding protein (0.01%) and trout sex
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Figure 2. Photomicrographs showing the luminal
epithelium (LE), glandular epithelium (GL), lamina
propria (LP), longitudinal smooth muscle (LM),
and circular smooth muscle (CM) of the uterus
from immature mice exposed for 3 days to (A)
DMSO, (B) 50 mg/kg BPA, (C) 75 mg/kg BPA, and
(D) E2. Note the increase in the height of the lumi-
nal epithelium in uteri exposed to 75 mg/kg BPA
and E2. H&E; magniﬁcation 470× .
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Figure 3. Immunolocalization of lactoferrin in the
luminal epithelium and glandular epithelium of the
uterus from immature mice exposed for 3 days to
(A) DMSO, (B) 50 mg/kg BPA, (C) 75 mg/kg BPA, and
(D) E2. Note the increase in lactoferrin expression
(red) in uteri exposed to 75 mg/kg BPA and E2. The
uterus exposed to 50 mg/kg BPA (B) represents one
animal that showed a maximal lactoferrin response
to BPA at this dose. Magniﬁcation 950× .
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Dsteroid-binding protein (0.1%) with low
affinity relative to [3H]dihydrotestosterone,
and to rat α -fetoprotein with negligible afﬁn-
ity (43). The presence of α -fetoprotein is par-
ticularly important during fetal and neonatal
development because it is believed to prevent
early exposure of the organism to endogenous
estrogens, thus preventing inappropriate sex-
ual differentiation of the brain (44). The
pharmacokinetics of BPA most likely acts to
increase its effective concentration in circula-
tion, making it more readily available to the
ER and thus enhancing its estrogenic activity
relative to the protein-bound estradiol. 
The uterotrophic assay has been tradition-
ally used to establish the estrogenic activity of
sex steroids and suspected environmental
estrogens (13,45). Our present study reveals
that BPA is able to induce a uterotrophic
effect, that is, an increase in wet weight of the
uterus, at only the highest concentration used
(100 mg/kg body weight). This assay suggests
that BPA is not a very potent estrogen mimic
in the CD-1 mouse, although at 5 mg/kg
body weight, BPA induced a significant
increase in the height of luminal epithelial
cells. These data demonstrate that the
uterotrophic assay is of limited value in deter-
mining the estrogenicity of a suspected envi-
ronmental estrogen because changes at the
cellular level were observed at significantly
lower doses than those at which a change in
wet weight occurred. Moreover, there was a
signiﬁcant effect on vaginal opening at even
lower BPA doses (0.1 mg/kg body weight). 
In conclusion, this work contributes to
the body of evidence showing that BPA acts
as an estrogen in vivo by inducing cellular
and biochemical changes in the mouse uterus
that are consistent with estrogenic activity.
Also, BPA was capable of inducing changes
in vaginal opening, uterine wet weight,
epithelial cell height, and lactoferrin expres-
sion in the CD-1 mouse, which establishes
that this strain is suitable for investigating the
effects of in utero exposure to BPA on devel-
opment and reproduction. Finally, this work
argues against using the mouse uterotrophic
assay as an end point for determining
estrogenicity of synthetic chemicals, and
demonstrates that it is essential to develop
alternative, more sensitive in vivo assays. 
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